Retinoids and retinoic acid receptor in cancer

European Journal of Cancer, Supplement

Volumn 1, Issue 2, 2003, Pages 13-18

  Lei, M ^a   De The H ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Arsenic; Leukemia; Receptors; Transformation; Vitamin A

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; HYBRID PROTEIN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; RETINOL DERIVATIVE;

ACUTE ABDOMEN; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE TARGETING; HEAD CANCER; HUMAN; LEUKOPLAKIA; NECK CANCER; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 2442495132     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00010-7     Document Type: Article

References (45)

1. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev Cancer. 1:2001;181-193
2. Dejean A., Bougueleret L., Grzeschick K., Tiollais P. Hepatitis virus DNA integration in a sequence homologous to v-erbA and steroid receptors genes in a hepatocellular carcinoma. Nature. 322:1986;70-72
3. de Thé H., Vivanco-Ruiz MdM., Tiollais P., Stunnenberg H., Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature. 343:1990;177-180
4. Chen J.-Y., Penco S., Ostrowski J., et al. R.A.R. specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14:1995;1187-1197
5. Degos L., Dombret H., Chomienne C., et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 85:1995;2643-2653
6. Melnick A., Licht J.D. Deconstructing a disease. RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia Blood. 93:1999;3167-3215
7. Brown D., Kogan S., Lagasse E., et al. A PML RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:1997;2551-2556
8. Huang M., Ye Y., Chen R., et al. Use of all trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood. 72:1988;567-572
9. Warrell R., de Thé H., Wang Z., Degos L. Acute promyelocytic leukemia. New Engl. J. Med. 329:1993;177-189
10. Quignon F., Chen Z., de Thé H. Retinoic acid and arsenic. towards oncogene targeted treatments of acute promyelocytic leukaemia Biochim. Biophys. Acta. 1333:1997;M53-M61
11. Zhu J., Lallemand-Breitenbach V., de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene. 20:2001;7257-7265
12. Minucci S., Maccarana M., Cioce M., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell. 5:2000;811-820
13. Lin R.J., Nagy L., Inoue S., Shao W.L., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 391:1998;811-814
14. Grignani F., de Matteis S., Nervi C., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818
15. Yoshida H., Kitamura K., Tanaka K., et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia. Possible role of the proteasome pathway. Cancer Res. 56:1996;2945-2948
16. Raelson J.V., Nervi C., Rosenauer A., et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 88:1996;2826-2832
17. Zhu J., Gianni M., Kopf E., et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc. Natl. Acad. Sci. USA. 96:1999;14807-14812
18. Mu Z.M., Chin K.V., Liu J.H., Lozano G., Chang K.S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14:1994;6858-6867
19. Quignon F., de Bels F., Koken M., Feunteun J., Ameisen J.-C., de Thé H. PML induces a caspase-independent cell death process. Nat Genet. 20:1998;259-265
20. Koken M.H.M., Linares-Cruz G., Quignon F., et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene. 10:1995;1315-1324
21. Terris B., Baldin V., Dubois S., et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 55:1995;1590-1597
22. Wang Z.-G., Ruggero D., Ronchetti S., et al. PML is essential for multiple apoptotic pathways. Nat Genet. 20:1998;266-272
23. Wang Z.G., Delva L., Gaboli M., et al. Role of PML in cell growth and the retinoic acid pathway. Science. 279:1998;1547-1551
24. Koken M.H.M., Puvion-Dutilleul F., Guillemin M.C., et al. The t(15;17) translocation alters a nuclear body in a RA-reversible fashion. EMBO J. 13:1994;1073-1083
25. Weis K., Rambaud S., Lavau C., et al. Retinoic acid regulates aberrant nuclear localization of PML/RARα in acute promyelocytic leukemia cells. Cell. 76:1994;345-356
26. Dyck J.A., Maul G.G., Miller W.H., Chen J.D., Kakizuka A., Evans R.M. A novel macromolecular structure is a target of the promyelocyte- retinoic acid receptor oncoprotein. Cell. 76:1994;333-343
27. Stuurman N., de Graaf A., Floore A., et al. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J. Cell Sci. 101:1992;773-784
28. Ishov A.M., Sotnikov A.G., Negorev D., et al. PML is critical for N.D.10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:1999;221-234
29. Lallemand-Breitenbach V., Zhu J., Puvion F., et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 193:2001;1361-1372
30. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood. 95:2000;2748-2752
31. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1996;1052-1061
32. 3 exerts dose- dependent dual effects on APL cells Blood. 89:1997;3345-3353
33. Chen G.Q., Shen Z.X., Wu F., et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia. 10:1996;825-828
34. Lallemand-Breitenbach V., Guillemin M.-C., Janin A., et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1999;1043-1052
35. Zhu J., Koken M.H.M., Quignon F., et al. Arsenic-induced PML targeting onto nuclear bodies. implications for the treatment of acute promyelocytic leukemia Proc. Natl. Acad. Sci. USA. 94:1997;3978-3983
36. vom Baur E., Zechel C., Heery D., et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15:1996;110-124
37. Muto A., Kizaki M., Kawamura C., et al A. novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia. 15:2001;1176-1184
38. Zhu Q., Zhang J.W., Zhu H.Q., et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood. 99:2002;1014-1022
39. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 7:2001;680-686
40. Rego E.M., He L.Z., Warrell R.P. Jr., Wang Z.G., Pandolfi P.P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA. 97:2000;10173-10178
41. Jing Y., Wang L., Xia L., et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 97:2001;264-269
42. Hong S.H., Yang Z., Privalsky M.L. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol. 21:2001;7172-7182
43. Merghoub T., Gurrieri C., Piazza F., Pandolfi P.P. Modeling acute promyelocytic leukemia in the mouse. new insights in the pathogenesis of human leukemias Blood Cells Mol Dis. 27:2001;231-248
44. Kogan S.C., Hong S.H., Shultz D.B., Privalsky M.L., Bishop J.M. Leukemia initiated by PMLRARalpha. the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable Blood. 95:2000;1541-1550
45. He L.Z., Tolentino T., Grayson P., et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 108:2001;1321-1330